CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
Enantyum® oral solution +1 moredrug
Likely dose
Enantyum® oral solution 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02209454
NCT02209454Phase 1Completed

Comparative Study of the Bioavailability of Dexketoprofen Trometamol Following Single Doses of 25mg Enantyum® Oral Solution vs. Keral® Tablets in Healthy Subjects

Menarini Group·interventional·Posted Aug 6, 2014·Updated Jul 9, 2015

In Brief

A Phase 1 clinical trial evaluating Enantyum® oral solution and Keral® tablet for Acute Pain. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the bioavailability of 25 mg DKP.TRIS given as an Enantyum® oral solution (Test formulation) and Keral® tablet (Reference formulation). In addition, this study intends to evaluate the safety and tolerability of Test and Reference formulations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Pain
CountriesUnited Kingdom
CollaboratorsSimbec Research

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 6, 2014
Enrollment StartApr 1, 2014
Primary CompletionMay 1, 2014
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.9 years ago

Interventions

Enantyum® oral solutiondrug

One dose of 25 mg DKP oral solution

Keral® tabletdrug

One dose of 25 mg DKP tablet